Abstract
Vascular endothelial growth factor (VEGF) is one of the main endogenous pro-angiogenic cytokines. Inhibition of the VEGF signaling pathways is an effective treatment for cancer patients. In addition, local anti- VEGF therapy was developed and established to treat proliferative diabetic retinopathy, age-related macular degeneration and retinal vein occlusion. For systemic administration of anti-VEGF drugs, serious side effects including hypertension or renal disorders have been observed. Evidence suggests that systemic effects might occur or develop in long-term treatment, despite limited resorption and minimal local side effects. Here, only limited data from clinical studies are available. The VEGF system is delicately balanced, and changes might result in deleterious effects.
This review provides a brief overview of the VEGF-system, and summarizes its relevance in proliferative eye diseases. The anti-VEGF drugs locally used to treat different disease conditions are discussed with their local and systemic side effects.
Keywords: Angiogenesis, anti-VEGF therapy, eye disease, VEGF.
Current Pharmaceutical Design
Title:Anti-VEGF Drugs in Eye Diseases: Local Therapy with Potential Systemic Effects
Volume: 21 Issue: 24
Author(s): Markus van der Giet, Cornelia Henkel, Mirjam Schuchardt and Markus Tolle
Affiliation:
Keywords: Angiogenesis, anti-VEGF therapy, eye disease, VEGF.
Abstract: Vascular endothelial growth factor (VEGF) is one of the main endogenous pro-angiogenic cytokines. Inhibition of the VEGF signaling pathways is an effective treatment for cancer patients. In addition, local anti- VEGF therapy was developed and established to treat proliferative diabetic retinopathy, age-related macular degeneration and retinal vein occlusion. For systemic administration of anti-VEGF drugs, serious side effects including hypertension or renal disorders have been observed. Evidence suggests that systemic effects might occur or develop in long-term treatment, despite limited resorption and minimal local side effects. Here, only limited data from clinical studies are available. The VEGF system is delicately balanced, and changes might result in deleterious effects.
This review provides a brief overview of the VEGF-system, and summarizes its relevance in proliferative eye diseases. The anti-VEGF drugs locally used to treat different disease conditions are discussed with their local and systemic side effects.
Export Options
About this article
Cite this article as:
Giet van der Markus, Henkel Cornelia, Schuchardt Mirjam and Tolle Markus, Anti-VEGF Drugs in Eye Diseases: Local Therapy with Potential Systemic Effects, Current Pharmaceutical Design 2015; 21 (24) . https://dx.doi.org/10.2174/1381612821666150225120314
DOI https://dx.doi.org/10.2174/1381612821666150225120314 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Redox mechanisms in pathological angiogenesis in the retina: roles for NADPH oxidase
Current Pharmaceutical Design Microcirculation of the Diabetic Foot
Current Pharmaceutical Design Development of RNA Aptamer-Based Therapeutic Agents
Current Medicinal Chemistry Models for the Study of Angiogenesis
Current Pharmaceutical Design Pharmacogenomics of Open-Angle Glaucoma
Current Pharmacogenomics and Personalized Medicine Toxins Targeting Voltage-Activated Ca<sup>2+</sup> Channels and their Potential Biomedical Applications
Current Topics in Medicinal Chemistry Basic and Clinical Aspects of Gene Therapy for Retinopathy Induced by Diabetes
Current Gene Therapy Atherosclerotic and Non-Atherosclerotic Coronary Heart Disease in Women
Current Medicinal Chemistry The Production of Solid Dosage Forms from Non-Degradable Polymers
Current Pharmaceutical Design From the Design to the Clinical Application of Thromboxane Modulators
Current Pharmaceutical Design Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis
Recent Patents on Biomedical Engineering (Discontinued) Treatment of Chronic Peripheral Arterial Disease
Current Vascular Pharmacology Subtypes of Antiphospholipid Antibodies in Neurologic Disorders: An Observational Study
Current Rheumatology Reviews Anti-Vegf Therapy for Ocular Diseases: Present and Future
Current Drug Targets Neovascular Age-related Macular Degeneration: Past, Present, and Future
Current Angiogenesis (Discontinued) Current Development in Encapsulated Cell Therapy for Degenerative Retinopathies
Current Tissue Engineering (Discontinued) ANN Classification and Modified Otsu Labeling on Retinal Blood Vessels
Current Signal Transduction Therapy Pituitary Adenylate Cyclase Activating Polypeptide: A Potential Neuroprotective Peptide
Current Pharmaceutical Design Regulation of Angiogenesis by Macrophages, Dendritic Cells, and Circulating Myelomonocytic Cells
Current Pharmaceutical Design Identifying Risk Factors for Clinically Significant Diabetic Macula Edema in Patients with Type 2 Diabetes Mellitus
Current Diabetes Reviews